AWA
SUPN icon

Arkadios Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Arkadios Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,799
Closed -$550K – 1359
2025
Q1 		$550K Buy
+16,799
New +$595K 0.02% 674

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Arkadios Wealth Advisors's SUPN Position: Q2 2025 in Review

Arkadios Wealth Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 16,799 shares — an estimated $550K sold.

Arkadios Wealth Advisors first reported a position in SUPN in Q1 2025 and held it in 1 quarter. The position peaked at $550K in Q1 2025. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Arkadios Wealth Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 16,799 Supernus Pharmaceuticals shares in Q2 2025, an estimated $550K.
  • Arkadios Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Arkadios Wealth Advisors's Supernus Pharmaceuticals position peaked at $550K in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.